Stem cells · Lesson 7 of 8 · 3 min

How does the FDA regulate stem cell products? Section 361 versus Section 351

The FDA sorts cell and tissue products into two categories, Section 361 and Section 351. Culture expansion usually puts an MSC product in the stricter one.

A researcher looking into a microscope

Key takeaways.

  • The FDA regulates stem cell products as human cells, tissues, and cellular and tissue-based products (HCT/Ps).
  • Section 361 covers products that are minimally manipulated and intended for homologous use.
  • Section 351 products are regulated as biological drugs and require BLA / IND approval.
  • Culture expansion of MSCs counts as more than minimal manipulation.
  • A narrow exception covers autologous cells removed and reimplanted in the same surgical procedure.
  • Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market.

Two regulatory categories

The FDA oversees human cells, tissues, and cellular and tissue-based products, known as HCT/Ps. A product falls into one of two categories.

A Section 361 HCT/P is regulated as human tissue. It needs registration and listing with the FDA only. A product qualifies when it is minimally manipulated and intended for homologous use.

A Section 351 product is regulated as a biological drug. It requires BLA / IND approval, the FDA's licensing and investigational drug routes. This category applies when a product is more than minimally manipulated or is used non-homologously.

Why culture expansion matters

Culture expansion means growing cells in the laboratory to increase their number. The FDA considers culture expansion of mesenchymal stem/stromal cells (MSCs) to be more than minimal manipulation, because expansion alters the biological characteristics of the cells.

This places most expanded MSC products in the Section 351 category. A culture-expanded MSC product therefore needs the IND / BLA route, not 361 registration.

The same surgical procedure exception

There is one exception clinicians often hear about. Autologous cells, meaning the patient's own, that are removed and reimplanted during the same surgical procedure are exempt from certain regulations. This allows point-of-care processing without BLA approval.

What this means in practice

Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market. Registration and listing is a different thing from BLA / IND approval.

Before offering any cell product, a clinician should know which category it falls into and why. State rules apply as well.

Educational content for healthcare professionals. Not a treatment recommendation. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses most clinics offer.

Stem cells: 0 of 8 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • How to work out which category a product falls into
  • Minimal manipulation and homologous use in detail
  • State-by-state compliance requirements
  • Safety considerations and documentation
  • Marketing claims and regulatory risk

Common questions.

What is the difference between a 361 and a 351 product?
A Section 361 HCT/P is regulated as human tissue and needs registration and listing only. A Section 351 product is regulated as a biological drug and requires BLA / IND approval.
Are culture-expanded MSCs a 361 product?
Generally no. The FDA considers culture expansion more than minimal manipulation, which places most expanded MSC products in the Section 351 category.
What is the same surgical procedure exception?
Autologous cells removed and reimplanted during the same surgical procedure are exempt from certain regulations. This allows point-of-care processing without BLA approval.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.